Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Myeloma • NCI-CCC Tumor Board Question • Mayo Clinic • NCI-CCC Myeloma Tumor Board Question • Mayo • ASCO 2024
Based on the IMROZ and BENEFIT data, would you recommend quadruplet therapy for non transplant eligible newly diagnosed multiple myeloma?
Answer from: Medical Oncologist at Academic Institution
Excellent question - to add citations for those who missed ASCO 2024 (I did since I was on inpatient!) and would like to jump to the manuscripts:
IMROZ: Isa-VRd versus VRd (Facon et al., PMID 38832972)
BENEFIT/IFM 2020-05: Isa-VRd versus Isa-Rd (Leleu et al., PMID 38830994)
Both trials enrolled p...
Sign in or Register to read more